Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Mr. Mark  Mintz

Corporate Senior Vice President & Chief Information Officer

Mr. Michael Gunnar Knell

Corporate Senior Vice President & Chief Accounting Officer

Mr. Matthew L. Daniel

Corporate Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer

Ms. Birgit  Girshick

Corporate Executive Vice President & Chief Operating Officer

Todd  Spencer

Corporate Vice President of Investor Relations

Prof. Julie  Frearson Ph.D.

Corporate Senior Vice President & Chief Scientific Officer

Mr. William D. Barbo

Corporate Executive Vice President of Community Relations

Mr. James C. Foster J.D.

Chief Executive Officer, President & Chairman

Mr. Joseph W. LaPlume

Corporate Executive Vice President of Corporate Development & Strategy

Ms. Flavia H. Pease

Corporate Executive Vice President & Chief Financial Officer

Nimi	Turukapitali suurus
Revvity, Inc.	0M
China Biotech Services Holdings Limited	0M
IDEXX Laboratories, Inc.	0M
Yunkang Group Limited	0M
Standard BioTools Inc.	0M
Sonic Healthcare Limited	0M
Sonic Healthcare Limited	0M
Quest Diagnostics Incorporated	0M
Qiagen N.V.	0M
Amoy Diagnostics Co., Ltd.	0M
WuXi AppTec Co., Ltd.	0M

Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. Konkurentide nimekiri

Peamised konkurendid